1614 related articles for article (PubMed ID: 25517309)
21. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
22. Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.
Asano R; Ikoma K; Sone Y; Kawaguchi H; Taki S; Hayashi H; Nakanishi T; Umetsu M; Katayose Y; Unno M; Kudo T; Kumagai I
J Biol Chem; 2010 Jul; 285(27):20844-9. PubMed ID: 20444691
[TBL] [Abstract][Full Text] [Related]
23. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
24. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system.
Asano R; Nakayama M; Kawaguchi H; Kubota T; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
FEBS J; 2012 Jan; 279(2):223-33. PubMed ID: 22074399
[TBL] [Abstract][Full Text] [Related]
25. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
[TBL] [Abstract][Full Text] [Related]
27. Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy.
Nakanishi T; Maru T; Tahara K; Sanada H; Umetsu M; Asano R; Kumagai I
Protein Eng Des Sel; 2013 Feb; 26(2):113-22. PubMed ID: 23118340
[TBL] [Abstract][Full Text] [Related]
28. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
29. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.
Stork R; Campigna E; Robert B; Müller D; Kontermann RE
J Biol Chem; 2009 Sep; 284(38):25612-9. PubMed ID: 19628871
[TBL] [Abstract][Full Text] [Related]
31. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
32. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
33. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
[TBL] [Abstract][Full Text] [Related]
34. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
35. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment.
Asano R; Kudo T; Nishimura Y; Makabe K; Hayashi H; Suzuki M; Tsumoto K; Kumagai I
J Biochem; 2002 Dec; 132(6):903-9. PubMed ID: 12473192
[TBL] [Abstract][Full Text] [Related]
36. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
[TBL] [Abstract][Full Text] [Related]
37. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
38. Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers.
Asano R; Hagiwara Y; Koyama N; Masakari Y; Orimo R; Arai K; Ogata H; Furumoto S; Umetsu M; Kumagai I
FEBS J; 2013 Oct; 280(19):4816-26. PubMed ID: 23890417
[TBL] [Abstract][Full Text] [Related]
39. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
40. The eIg technology to generate Ig-like bispecific antibodies.
Kühl L; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
